Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

被引：2
|
作者：
Zipp, Lisa
Saliba, Rima M.
Valverde, Rosamar [1 ]
Okoroji, Grace-Julia
Korbling, Martin
Samuels, Barry I.
Abruzzo, Lynne V. [2 ]
Alousi, Amin M.
Andersson, Borje S. [1 ]
Hosing, Chitra M.
Erwin, Bill
Anderlini, Paolo [1 ]
Popat, Uday R.
Kebriaei, Partow
Macapinlac, Homer A.
Champlin, Richard [1 ]
Khouri, Issa F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2005.2005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：875 / 876
页数：2
相关论文
共 50 条
  • [1] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [2] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-Cell lymphoma (DLBCL):: Impact of the IPI and PET status
    Alousi, Amin M.
    Hosing, Chitra
    Saliba, Rima M.
    Valverde, Rosainar B.
    Maadani, Farzaneh
    Korbling, Martin
    Okoroji, Grace J.
    Fayad, Luis E.
    Stachowiak, Anne M.
    Erwin, William D.
    Anderlini, Paolo
    de Lima, Marcos J.
    Giralt, Sergio A.
    Popat, Uday R.
    Kebriaei, Partow
    Ueno, Naoto T.
    McLaughlin, Peter W.
    Pro, Barbara
    Wang, Michael
    Rodriguez, Alma
    Hagemeister, Fredrick B.
    Macapinlac, Homer A.
    Podoloff, Donald A.
    Champlin, Richard E.
    Khouri, Issa F.
    BLOOD, 2007, 110 (11) : 191A - 192A
  • [4] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
    Chic Acevedo, C.
    Garcia Torres, E.
    Llamas Poyato, M. J.
    Rodriguez, G.
    Martin, C.
    Rojas, R.
    Serrano, J.
    Tabares, S.
    Vallejo, J. A.
    Sanchez, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
  • [5] Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-Cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial.
    Morschhauser, F
    Huglo, D
    Martinelli, G
    Paganelli, G
    Zinzani, PL
    Hadjiyiannakis, D
    Liberati, A
    Illidge, T
    Milpied, N
    Stein, H
    Kalmus, J
    Morel, P
    Reimann, U
    Marcus, R
    BLOOD, 2004, 104 (11) : 41A - 41A
  • [6] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [7] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
    Ciochetto, Chiara
    Botto, Barbara
    Passera, Roberto
    Bello, Marilena
    Benevolo, Giulia
    Boccomini, Carola
    Castellino, Alessia
    Chiappella, Annalisa
    Freilone, Roberto
    Nicolosi, Maura
    Orsucci, Lorella
    Pecoraro, Clara
    Pregno, Patrizia
    Bisi, Gianni
    Vitolo, Umberto
    ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1619 - 1626
  • [8] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
    Chiara Ciochetto
    Barbara Botto
    Roberto Passera
    Marilena Bellò
    Giulia Benevolo
    Carola Boccomini
    Alessia Castellino
    Annalisa Chiappella
    Roberto Freilone
    Maura Nicolosi
    Lorella Orsucci
    Clara Pecoraro
    Patrizia Pregno
    Gianni Bisi
    Umberto Vitolo
    Annals of Hematology, 2018, 97 : 1619 - 1626
  • [9] Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma
    Alcindor T.
    Witzig T.E.
    Current Treatment Options in Oncology, 2002, 3 (4) : 275 - 282
  • [10] Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant
    Arnason, Jon E.
    Luptakova, Katarina
    Rosenblatt, Jacalyn
    Tzachanis, Dimitrios
    Avigan, David
    Zwicker, Jeffrey I.
    Levine, James
    Kim, Michelle
    Parker, J. Anthony
    Grant, Barbara
    Joyce, Robin M.
    ACTA HAEMATOLOGICA, 2015, 133 (04) : 347 - 353
12345